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See Article, pages 535–547Cigarette smoke exposure, whether passive or active,
carries a high disease burden worldwide [1]. In a recent
comprehensive assessment of the mortality attributable
to modiﬁable risk factors in the US adult population,
tobacco use was held responsible for 467,000 deaths
(approximately one out of ﬁve) in 2005 [2]. Despite the
large body of evidence documenting the pluriorgan mor-
bidity of tobacco, reports investigating the impact of
cigarette smoking on pathogenesis of liver injury have
long remained scant. Initial evidence arose from two ret-
rospective studies suggesting that cigarette smoking may
increase prevalence and/or severity of alcoholic [3] and
HBV-related cirrhosis [4]. Accordingly, two recent stud-
ies in patients with primary biliary cirrhosis identiﬁed
tobacco use as an independent predictor of advanced
ﬁbrosis at presentation [5,6]. In contrast, in patients with
chronic hepatitis C, the impact of tobacco use on ﬁbro-
sis progression remains controversial [7,8] and available
data would suggest that cigarette smoking may aggra-
vate necroinﬂammation, thereby contributing to acceler-
ated ﬁbrogenesis [7–10]. Finally, in line with the
carcinogenic properties of tobacco in several organs, a
number of studies indicate that cigarette smoking is
associated with an increased incidence of hepatocellular
carcinoma in cirrhotic patients [11–14].
Non-alcoholic fatty liver disease (NAFLD), the hepa-
tic hallmark of the metabolic syndrome, is a worrisome0168-8278/$36.00  2009 European Association for the Study of the Liver.
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E-mail address: ariane.mallat@hmn.aphp.fr (A. Mallat)rising cause of chronic liver injury closely linked to a
sedentary lifestyle and habits associated with it. Besides
its known impact on liver-related mortality in the sub-
group of patients that progress to NASH [15], NAFLD
has also been identiﬁed as an independent risk factor of
atherosclerosis and cardiovascular diseases [16–18]. In
this issue of the Journal, Yuan et al. provide novel evi-
dence demonstrating that tobacco smoke exposure
may accelerate the development of experimental
NAFLD [19]. The study extends an earlier report from
the group showing that in apo B transgenic mice,
chronic environmental (second-hand) smoke exposure
is associated to features of atherosclerotic plaque initia-
tion [20]. Using the same model, the authors now show
that exposure to second-hand smoke potentiates steato-
genesis elicited by a high-fat diet, as assessed by red oil
staining and hepatic triglyceride quantiﬁcation [19].
Since increased hepatic lipogenesis has been shown to
account for approximately 30% of triglyceride accumu-
lation in steatotic livers [21], the authors subsequently
investigate the impact of second-hand smoke on liver
lipogenic pathways. Interestingly, cultured hepatocyte
cell lines exposed to second-hand smoke display
enhanced accumulation of triglycerides and increased
expression of Acetyl CoA Carboxylase (ACC) and Fatty
acid synthase (FAS), two key enzymes governing hepa-
tic synthesis of fatty acids. These data therefore indicate
that the steatogenic properties of tobacco smoke are at
least partly explained by a direct eﬀect on hepatocytes.
In deciphering molecular determinants underlying
tobacco-dependent activation of lipogenesis, the authors
focus on two key regulators of lipid metabolism, Sterol
regulatory element binding protein-1c (SREBP-1c) and
AMP-activated protein kinase (AMP kinase). SREBPs
are a family of basic-helix-loop-helix-leucine zipperPublished by Elsevier B.V. All rights reserved.
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embedded in the endoplasmic reticulum [22]. Activation
of SREBPs requires proteolytic cleavage, thereby allow-
ing nuclear translocation and transcriptional activation
of target lipogenic genes [23]. Whereas SREBP-2
governs synthesis of cholesterol, SREBP-1c promotes
biosynthesis of fatty acids by upregulating enzymes such
as ACC and FAS. The serine/threonine protein kinase
AMP kinase is an energy sensor that acts as a metabolic
master switch [24]. The phosphorylated active form of
the enzyme simultaneously inhibits energy-consuming
biosynthetic pathways such as lipogenesis and activates
ATP-producing catabolic pathways such as fatty acid
oxidation [24]. It has been shown that AMP kinase
inhibits fatty acid synthesis both by phosphorylating
target lipogenic enzymes and downregulating expression
of transcription factors such as SREBP-1c [25–27]. In
accordance with these data, Yuan et al. now demon-
strate that second-hand smoke exposure inhibits phos-
phorylation and activation of AMP kinase, thereby
resulting in increased SREBP-1 activity and enhance-
ment of fatty acid synthesis [19].
This study provides compelling experimental evi-
dence supporting a role of tobacco smoke exposure
as a cofactor of NAFLD. In line with the present
report, second-hand smoke exposure has also recently
been shown to enhance alcoholic steatosis in a model
of apoE= mice fed an alcohol diet for 4 weeks [28];
however, in animals fed a control diet, tobacco smoke
exposure had no eﬀect on liver triglyceride concentra-
tion [28]. Taken together, these data suggest that
tobacco exposure may behave as a cofactor of steato-
genesis of diverse origins, by enhancing hepatocyte
lipogenesis. Nonetheless, the data by Yuan et al. war-
rant conﬁrmation in classical models of NAFLD, such
as genetically obese leptin deﬁcient ob/ob mice or mice
fed a high-fat diet; indeed, apoB transgenic mice fed a
high-fat diet are primarily used as a model of athero-
sclerosis. Moreover, the data also raise several ques-
tions with respect to the mechanisms underlying
steatogenic properties of second-hand smoke. Thus,
besides the aforementioned enhancement in hepatic
lipogenesis, sources of hepatic lipids in the steatotic
liver include increased lipolysis in the insulin-resistant
adipose tissue, reduced channeling of fatty acids to
the b-oxidation pathway in the liver, and/or reduced
fat export in the form of very low-density lipoproteins
[23]. Future experiments should therefore investigate
the impact of tobacco smoke exposure on these path-
ways, in particular on fatty acid inﬂux, inasmuch as
recent studies indicate that tobacco exposure predis-
poses to the development of insulin resistance [29,30].
Also, it is well established that AMP kinase is a major
inhibitor of liver glucose output and mediates the
hypoglycaemic eﬀects of adiponectin and of anti-dia-
betic drugs such as metformin and thiazolinediones[24,25]. These data therefore suggest that tobacco
smoke might enhance insulin resistance by inhibiting
hepatic AMP kinase. Interestingly, the authors previ-
ously showed that second-hand smoke exposure
reduces serum levels of adiponectin in apoB mice
[20]. Whether this decrease in adiponectin contributes
to the tobacco-dependent inhibition of AMP kinase
remains to be investigated.
Finally, the data reported by Yuan et al. raise the
question as to the clinical relevance of these experi-
mental ﬁndings, an issue that remains open, given
the scarcity of data. As already mentioned, it has been
shown that tobacco use predisposes to the develop-
ment of insulin resistance [17,31,32]. Moreover, ﬁnd-
ings from a large survey of US adolescents indicate
that passive and active smoke exposure are strong
independent predictors of the presence of the meta-
bolic syndrome [33]. These observations indirectly sug-
gest that tobacco use may indeed enhance NAFLD,
the hepatic hallmark of the metabolic syndrome. How-
ever, very few studies have speciﬁcally evaluated the
potential impact of tobacco use on metabolic steatosis
heretofore and results have been discrepant. Thus, a
cross-sectional German health survey in 2500 adults
found no relationship between tobacco use and the
presence of NAFLD as assessed by ultrasonography
[34]. In contrast, in a longitudinal study of 368 males
with a suspicion of NAFLD, as deﬁned by unex-
plained ALAT elevations, onset of smoking during
the course of follow-up was an independent predictor
of ALAT deterioration [35].
In summary, accumulating data suggest that passive
or active tobacco exposure may belong to environmen-
tal stressors contributing to the progression of liver
injury. The report by Yuan et al. extends this assump-
tion to NAFLD and provides compelling evidence indi-
cating that tobacco smoke might alter the regulatory
eﬀect of AMP kinase on lipid metabolism. Future stud-
ies should closely investigate the clinical relevance of
these ﬁndings. Nevertheless, in the meantime, tobacco
cessation might be considered in the management of
patients with NAFLD.
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